Study to Understand Novel Biomarkers in Researching Dementia
NCT06547099
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer Disease
- Mild Cognitive Impairment
- Dementia
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Washington University School of Medicine
- Last updated on ClinicalTrials.gov
- September 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Missouri · 1
- Washington University School of Medicine · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.